Alpha Cognition (XCNQ:ACOG) Days Payable : 0.00 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Alpha Cognition Days Payable?

Alpha Cognition's average Accounts Payable for the three months ended in Mar. 2024 was C$0.68 Mil. Alpha Cognition's Cost of Goods Sold for the three months ended in Mar. 2024 was C$0.00 Mil.

The historical rank and industry rank for Alpha Cognition's Days Payable or its related term are showing as below:

XCNQ:ACOG's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 148.145
* Ranked among companies with meaningful Days Payable only.

Alpha Cognition's Days Payable stayed the same from Mar. 2023 (0.00) to Mar. 2024 (0.00). stayed the same

Alpha Cognition Days Payable Historical Data

The historical data trend for Alpha Cognition's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alpha Cognition Days Payable Chart

Alpha Cognition Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Days Payable

Alpha Cognition Quarterly Data
	Jan20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Days Payable	Get a 7-Day Free Trial										-	-	-	-	-

Competitive Comparison of Alpha Cognition's Days Payable

For the Biotechnology subindustry, Alpha Cognition's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alpha Cognition's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alpha Cognition's Days Payable distribution charts can be found below:

* The bar in red indicates where Alpha Cognition's Days Payable falls into.

Alpha Cognition Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Alpha Cognition's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (2.739	+	0.639)	/	2 )	/	0	*	365
=	1.689					/	0	*	365
=	N/A

Alpha Cognition's Days Payable for the quarter that ended in Mar. 2024 is calculated as:

	Days Payable (Q: Mar. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2023 )	+	Accounts Payable (Q: Mar. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
=	( (0.639	+	0.712)	/	2 )	/	0	*	365 / 4
=	0.6755					/	0	*	365 / 4
=	N/A

Alpha Cognition Days Payable Related Terms

Thank you for viewing the detailed overview of Alpha Cognition's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Alpha Cognition (XCNQ:ACOG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alpha Cognition Inc (XCNQ:ACOG) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

ACOGF:USA

Address

301 - 1228 Hamilton Street, Vancouver, BC, CAN, V6B 6L2

Website

https://www.alphacognition.com

Alpha Cognition Inc is a clinical stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, and Cognitive Impairment with Mild Traumatic Brain Injury (mTBI) for which there are limited or no treatment options. The Company is focused on the development of ALPHA-1062 for the treatment of mild-to-moderate Alzheimer's disease and completed an NDA filing to the FDA in September 2023. The company anticipates an FDA approval in mid-2024. The Company's ALPHA-1062 development program is primarily focused on clinical and regulatory development, Chemistry, Manufacturing and Control (CMC) development, and commercial readiness.

Alpha Cognition (XCNQ:ACOG) Headlines

No Headlines